767 research outputs found

    Semiarid watershed response in central New Mexico and its sensitivity to climate variability and change

    Get PDF
    Hydrologic processes in the semiarid regions of the Southwest United States are considered to be highly susceptible to variations in temperature and precipitation characteristics due to the effects of climate change. Relatively little is known about the potential impacts of climate change on the basin hydrologic response, namely streamflow, evapotranspiration and recharge, in the region. In this study, we present the development and application of a continuous, semi-distributed watershed model for climate change studies in semiarid basins of the Southwest US. Our objective is to capture hydrologic processes in large watersheds, while accounting for the spatial and temporal variations of climate forcing and basin properties in a simple fashion. We apply the model to the Río Salado basin in central New Mexico since it exhibits both a winter and summer precipitation regime and has a historical streamflow record for model testing purposes. Subsequently, we use a sequence of climate change scenarios that capture observed trends for winter and summer precipitation, as well as their interaction with higher temperatures, to perform long-term ensemble simulations of the basin response. Results of the modeling exercise indicate that precipitation uncertainty is amplified in the hydrologic response, in particular for processes that depend on a soil saturation threshold. We obtained substantially different hydrologic sensitivities for winter and summer precipitation ensembles, indicating a greater sensitivity to more intense summer storms as compared to more frequent winter events. In addition, the impact of changes in precipitation characteristics overwhelmed the effects of increased temperature in the study basin. Nevertheless, combined trends in precipitation and temperature yield a more sensitive hydrologic response throughout the year

    Conceptual mechanization studies for a horizon definition spacecraft attitude control subsystem, phase A, part II, 10 October 1966 - 29 May 1967

    Get PDF
    Attitude control subsystem for spin stabilized spacecraft for mapping earths infrared horizon radiance profiles in 15 micron carbon dioxide absorption ban

    Mapping Water Availability, Cost and Projected Consumptive Use in the Eastern United States with Comparisons to the West

    Get PDF
    The availability of freshwater supplies to meet future demand is a growing concern. Water availability metrics are needed to inform future water development decisions. Furthermore, with the help of water managers, water availability was mapped for over 1300 watersheds throughout the 31-contiguous states in the eastern U.S. complimenting a prior study of the west. The compiled set of water availability data is unique in that it considers multiple sources of water (fresh surface and groundwater, wastewater and brackish groundwater); accommodates institutional controls placed on water use; is accompanied by cost estimates to access, treat and convey each unique source of water, and; is compared to projected future growth in consumptive water use to 2030. Although few administrative limits have been set on water availability in the east, water managers have identified 315 fresh surface water and 398 fresh groundwater basins (with 151 overlapping basins) as Areas of Concern (AOCs) where water supply challenges exist due to drought related concerns, environmental flows, groundwater overdraft, or salt water intrusion. This highlights a difference in management where AOCs are identified in the east which simply require additional permitting, while in the west strict administrative limits are established. Although the east is generally considered water rich roughly a quarter of the basins were identified as AOCs; however, this is still in strong contrast to the west where 78% of the surface water basins are operating at or near their administrative limit. There was little effort noted on the part of eastern or western water managers to quantify non-fresh water resource

    Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis

    Get PDF
    Novel drugs to treat human African trypanosomiasis (HAT) are still urgently needed despite the recent addition of nifurtimox-eflornithine combination therapy (NECT) to WHO Model Lists of Essential Medicines against second stage HAT, where parasites have invaded the central nervous system (CNS). The pharmacology of a potential orally available lead compound, N-methoxy-6-{5-[4-(N-methoxyamidino) phenyl]-furan-2-yl}-nicotinamidine (DB844), was evaluated in a vervet monkey model of second stage HAT, following promising results in mice. DB844 was administered orally to vervet monkeys, beginning 28 days post infection (DPI) with Trypanosoma brucei rhodesiense KETRI 2537. DB844 was absorbed and converted to the active metabolite 6-[5-(4-phenylamidinophenyl)-furanyl-2-yl]-nicotinamide (DB820), exhibiting plasma C(max) values of 430 and 190 nM for DB844 and DB820, respectively, after the 14th dose at 6 mg/kg qd. A 100-fold reduction in blood trypanosome counts was observed within 24 h of the third dose and, at the end of treatment evaluation performed four days post the last drug dose, trypanosomes were not detected in the blood or cerebrospinal fluid of any monkey. However, some animals relapsed during the 300 days of post treatment monitoring, resulting in a cure rate of 3/8 (37.5%) and 3/7 (42.9%) for the 5 mg/kg×10 days and the 6 mg/kg×14 days dose regimens respectively. These DB844 efficacy data were an improvement compared with pentamidine and pafuramidine both of which were previously shown to be non-curative in this model of CNS stage HAT. These data show that synthesis of novel diamidines with improved activity against CNS-stage HAT was possible

    3 W of single-frequency output at 532 nm by intracavity frequency doubling of a diode-bar-pumped Nd:YAG ring laser 3 W of single-frequency output at 532 nm by intracavity frequency doubling of a diode-bar-pumped Nd:YAG ring laser

    No full text
    A beam-shaped 20W diode-bar has longitudinally pumped a Nd:YAG laser in a ring configuration. Unidirectional single-frequency operation is enforced by a Faraday rotator. Intracavity frequency doubling, using a KTP crystal has produced 3W of stable, single-frequency TEMoo output at 532nm

    B₂cat₂-Mediated Reduction of Sulfoxides to Sulfides

    Get PDF
    An efficient and operationally simple method for the reduction of sulfoxides to sulfides has been developed using bis(catecholato)diboron (B₂cat₂) as a reducing agent. The present method accommodates various functional groups which are generally prone to reduction: halides, alkynes, carbonyls, nitriles, and heterocycles are totally intact, and only sulfoxide moieties undergo reduction chemoselectively. Moreover, the remaining diboron and the resulting boron‐containing wastes are readily removable, the practicality of this protocol being thus demonstrated

    Efficacy, safety, and dose of Pafuramidine, a new oral drug for treatment of first stage sleeping sickness, in a phase 2a clinical study and phase 2b randomized clinical studies

    Get PDF
    Sleeping sickness (human African trypanosomiasis [HAT]) is caused by protozoan parasites and characterized by a chronic progressive course, which may last up to several years before death. We conducted two Phase 2 studies to determine the efficacy and safety of oral pafuramidine in African patients with first stage HAT.; The Phase 2a study was an open-label, non-controlled, proof-of-concept study where 32 patients were treated with 100 mg of pafuramidine orally twice a day (BID) for 5 days at two trypanosomiasis reference centers (Angola and the Democratic Republic of the Congo [DRC]) between August 2001 and November 2004. The Phase 2b study compared pafuramidine in 41 patients versus standard pentamidine therapy in 40 patients. The Phase 2b study was open-label, parallel-group, controlled, randomized, and conducted at two sites in the DRC between April 2003 and February 2007. The Phase 2b study was then amended to add an open-label sequence (Phase 2b-2), where 30 patients received pafuramidine for 10 days. The primary efficacy endpoint was parasitologic cure at 24 hours (Phase 2a) or 3 months (Phase 2b) after treatment completion. The primary safety outcome was the rate of occurrence of World Health Organization Toxicity Scale Grade 3 or higher adverse events. All subjects provided written informed consent.; Pafuramidine for the treatment of first stage HAT was comparable in efficacy to pentamidine after 10 days of dosing. The cure rates 3 months post-treatment were 79% in the 5-day pafuramidine, 100% in the 7-day pentamidine, and 93% in the 10-day pafuramidine groups. In Phase 2b, the percentage of patients with at least 1 treatment-emergent adverse event was notably higher after pentamidine treatment (93%) than pafuramidine treatment for 5 days (25%) and 10 days (57%). These results support continuation of the development program for pafuramidine into Phase 3
    corecore